A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Gemcitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TB-01; TROPION-Breast01
- Sponsors AstraZeneca; AstraZeneca AB
- 03 Sep 2024 According to an AstraZeneca media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress, September 13 to 17, 2024.
- 04 Jun 2024 Results of Patient-reported outcomes , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2024 This study has been Completed in Netherlands, According to European Clinical Trials Database record.